Hundreds of laid-off CDC employees in US are being reinstated
The US Department of Health and Human Services confirmed reinstatement notices went out to the former Centers for Disease Control and Prevention employees, but provided few details.
About 2,400 CDC employees lost their jobs in a wave of cuts across federal health agencies in early April, according to a tally at the time.
Whole CDC programs were essentially shut down, including some focused on smoking, lead poisoning, gun violence, asthma and air quality, and workplace safety and health. The entire office that handles Freedom of Information Act requests was shuttered. Infectious disease programs took a hit, too, including programs that fight outbreaks in other countries, labs focused on HIV and hepatitis in the US, and staff trying to eliminate tuberculosis.
An estimated 200 of the reinstated workers are based in the CDC's National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention, HHS officials confirmed. Staffers at a CDC lab that does testing for sexually transmitted diseases are being brought back, said one CDC employee who wasn't authorized to discuss what happened and spoke to The Associated Press on condition of anonymity.
Also reinstated are an estimated 150 employees at the CDC's National Center for Environmental Health, including people staffing a lab that works on lead poisoning, according to the union and employees.
Layoffs at federal agencies were challenged in lawsuits, with judges in some cases ordering federal agencies to halt terminations of employees.
Officials at HHS have never detailed how they made the layoff decisions in the first place. And they did not answer questions about why the notices went out, or how decisions were made about who to bring back.
HHS spokesperson Andrew Nixon said the agency was streamlining operations and that 'the nation's critical public health functions remain intact and effective.'
"The Trump Administration is committed to protecting essential services — whether it's supporting coal miners and firefighters through NIOSH, safeguarding public health through lead prevention, or researching and tracking the most prevalent communicable diseases,' he said.
The reinstatements don't undo the damage being done by Kennedy and the Trump administration to federal public health, said members of Fired But Fighting, a group of affected CDC workers who have helped organize rallies in Atlanta. The most recent was in the rain on Tuesday, at which some attendees called for Kennedy to resign.
'Bringing a few hundred people back to work out of thousands fired is a start, but there are still countless programs at CDC that have been cut, which will lead to increased disease and death,' one of the group's founding members, Abby Tighe, said in a statement.
This is not the first time that employees at the Atlanta-based agency were told they were being terminated only to then be told to come back. After an earlier round of termination notices went out in February, about 180 CDC employees in March were told to come back.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Can't sleep? New research shows ancient Indian and Chinese exercises enhance sleep quality
Struggling to fall asleep or stay asleep through the night? You're not alone. Insomnia now affects over 16% of people around the world, and it's only getting worse with today's busy, stressful lifestyles. While therapy and sleep medications can help, they're not always easy to access. A new study shows that simple movement-based practices like yoga, tai chi, walking, and jogging could be just as effective. These ancient, natural remedies don't just relax your body; they also help reset your sleep rhythm. If you're looking for a gentle, affordable way to sleep better, these time-tested techniques are worth trying. Global insomnia statistics: Why the world is struggling to sleep Insomnia is no longer a personal issue; it's a widespread health concern. Recent research reveals that 16.2% of the global population suffers from insomnia, and around 8% deal with more severe forms of it. In the United States, the CDC reports that 14.5% of adults experience chronic sleep difficulties. Traditional treatments such as CBT-i are highly effective but often require structured sessions with trained therapists. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it better to shower in the morning or at night? Here's what a microbiologist says CNA Read More Undo For many, the cost and availability of this therapy are barriers. This is where physical activity, particularly gentle and mindful forms like yoga, tai chi, walking, and jogging, may offer a promising solution. Study reveals yoga and tai chi improve sleep quality naturally A 2024 meta- analysis published in the journal Nature and Science of Sleep explored how various physical activities impact sleep. It concluded that regular participation in yoga, tai chi, walking, and jogging significantly improves sleep quality, sometimes even rivaling CBT-i. Yoga for insomnia was found to increase sleep duration by up to two hours and improve sleep efficiency by 15%, thanks to its focus on mindfulness, breathwork, and relaxation. Tai chi for better sleep, a slow and meditative martial art from China, showed long-term sleep improvements that lasted up to two years with consistent practice. Walking and jogging, though more aerobic, were linked to reduced stress, improved mood, and a more stable circadian rhythm, helping regulate your natural sleep-wake cycle. How gentle exercises help you sleep better What makes these practices effective is their impact on the nervous system. Yoga and tai chi reduce activation of the sympathetic nervous system, your "fight or flight" stress response, and instead stimulate the parasympathetic nervous system, which helps the body relax and prepare for rest. Aerobic activities like walking and jogging also help by Lowering cortisol (the stress hormone) Boosting serotonin and melatonin (sleep-regulating hormones) Reducing anxiety and depressive symptoms Reinforcing your internal body clock Why natural sleep remedies like yoga and tai chi are so effective One of the most encouraging aspects of these findings is accessibility. Unlike therapy or medication, yoga, tai chi, walking, and jogging require little to no cost and can be done in your living room, neighbourhood park, or even during a lunch break. They also provide wide-ranging health benefits, including Better cardiovascular function Improved balance and flexibility Enhanced mood and mental health Lower risk of chronic diseases These lifestyle-based solutions address the root causes of insomnia rather than masking symptoms. Lifestyle habits that may be ruining your sleep Modern sleep struggles often stem from overstimulation and irregular habits. Some common culprits include High-stress jobs and work-from-home burnout Too much screen time, especially before bed Irregular sleep schedules Exposure to artificial light at night Overthinking and anxiety about not sleeping Ironically, worrying about sleep can itself worsen insomnia. In this context, gentle movement practices help introduce structure, calm, and body awareness, creating a healthier sleep environment from within. The growing body of research shows that natural movement-based practices can be a low-risk, highly effective solution to insomnia. Whether you're aiming to sleep more soundly without medication or improve your overall wellbeing, incorporating yoga, tai chi, walking, or jogging into your daily routine could make a lasting difference. Small changes in movement may lead to major improvements in your rest. And in the long run, that could translate to a better mood, sharper focus, and a healthier life. Also Read: Strong calves, your clue to a long life: 7 simple exercises to build strength and stability
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Dr Reddy's Q1 result: Net profit up 2%, revenue hits record ₹8,545 crore
Hyderabad-based pharma major Dr Reddy's Laboratories (DRL) posted a consolidated net profit of ₹1,417 crore in the first quarter of financial year 2026 (Q1 FY26), a 2 per cent rise from ₹1,392 crore a year ago. The company clocked its highest-ever quarterly revenue at ₹8,545 crore, up 11 per cent year-on-year (Y-o-Y) from ₹7,672 crore. The increase in profit and revenue was attributed to new product launches and price hikes during the quarter. Sequentially, revenue was flat, with a marginal 0.4 per cent rise, while net profit declined by 11 per cent. G V Prasad, co-chairman and managing director, DRL, said: 'We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio.' Dr Reddy's is planning a major global rollout of semaglutide beginning in 2026, targeting 87 countries—including India, Brazil, Canada, and Turkey—subject to local patent expiries. In countries without active patents, launches will begin earlier. In India and Brazil, where the patent expires in March 2026, the company is targeting Day 1 launches. Erez Israeli, chief executive officer, DRL, said: 'The semaglutide launch is very important to us. It reflects our focus on business development, resource optimisation, and cost alignment for future growth. While there are execution risks, I'm confident we'll overcome them and continue our growth trajectory. Our pipeline includes 26 peptide-based GLP-1 products, expected to launch over the next decade.' Despite ongoing litigation with Novo Nordisk in India regarding the validity of the semaglutide patent, Dr Reddy's does not anticipate any delays or disruptions to its commercialisation plans. The company expects significant topline contribution from semaglutide, citing growing global demand for GLP-1 therapies in diabetes and weight management. Priced lower than Novo's offering (₹17,000 per month), Dr Reddy's plans to use its integrated manufacturing to enhance accessibility. Semaglutide is the first of 26 GLP-1 peptide-based drugs the company plans to launch globally over the next decade, with timing based on regional IP clearance. Dr Reddy's has guided for capital expenditure of approximately ₹2,700 crore in FY26, with major investments toward expanding peptide and biosimilar capacity in line with product-specific requirements. Segment Performance Global Generics: Revenue stood at ₹8,060 crore, up 10 per cent Y-o-Y, supported by new launches and stable volumes. North America: Revenue was ₹3,412 crore, down 11 per cent Y-o-Y due to price erosion in key products like Lenalidomide. The company launched five new products and filed one ANDA with the USFDA. As of June 2025, 73 filings are pending, including 70 ANDAs (43 Para IVs, 22 with potential First-to-File status) and three NDAs. Europe: Revenue surged 142 per cent Y-o-Y to ₹1,274 crore, driven by the NRT acquisition. The NRT business contributed ₹670 crore. Germany reported ₹320 crore (up 13 per cent), the UK ₹170 crore (up 10 per cent), and the rest of Europe ₹120 crore (up 30 per cent). Growth was led by new launches and forex gains, partly offset by price erosion. Thirteen new products were launched. Emerging Markets: Revenue rose 18 per cent Y-o-Y to ₹1,404 crore. Russia contributed ₹710 crore (up 28 per cent), the Commonwealth of Independent States and Romania ₹200 crore (up 2 per cent), and the rest of world territories ₹500 crore (up 13 per cent). A total of 26 new products were launched across these regions. Pharmaceutical Services and Active Ingredients: Revenue rose 7 per cent Y-o-Y to ₹818 crore, supported by new API launches, forex gains, and pharmaceutical services expansion. The company filed 12 Drug Master Files globally during the quarter. The results were announced post market hours. Dr Reddy's shares rose 0.58 per cent, closing at ₹1,247.50 apiece on the BSE.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Natco Pharma to acquire 35.75% stake in Adcock Ingram for ₹2,000 cr
The proposed Rs 2,000 crore deal will give Natco Pharma a strategic foothold in South Africa, with transaction completion expected within four months subject to approvals Sanket Koul New Delhi In a bid to enter the African market, Natco Pharma on Wednesday announced that it has submitted a firm intention for a ZAR 4 billion (Rs 2,000 crore) cash offer to acquire a minority stake in South Africa-based drugmaker Adcock Ingram Holdings (AIHL). If approved, the Hyderabad-based company will hold a 35.75 per cent stake in Adcock Ingram by offering ZAR 75.00 ($4.271) per share to minority stakeholders. The deal gives Natco a gateway into South Africa, with AIHL holding a 10 per cent share of the private pharmaceutical market in the country. It is also the largest supplier of hospital and critical care products in South Africa. This transaction would consolidate Natco's existing 0.80 per cent stake, making it the second-largest shareholder in AIHL, behind the Bidvest Group, which holds the remaining 64.25 per cent. 'Post-transaction, Natco will consolidate 35.75 per cent of AIHL's net profits in Natco's financial results in accordance with its shareholding,' the company said in a regulatory filing. If the deal proceeds, Adcock Ingram will be delisted from the Johannesburg Stock Exchange (JSE) and will continue to operate as a private South African business. Rajeev Nannapaneni, chief executive officer and vice-chairman of Natco Pharma, said the proposed acquisition would help the company tap into new revenue streams and expand its presence in one of the largest and fastest-growing emerging markets. In return, AIHL is expected to leverage Natco's research and development capabilities, regulatory expertise, and global marketing network to support local leadership and expansion into new markets. 'AIHL will benefit from a partnership with a research-focused, innovative, and vertically integrated pharmaceutical company, and over time, South Africans will be beneficiaries of wider access to affordable medicines,' said Andrew Hall, chief executive officer, AIHL. Valued at an estimated ZAR 11 billion ($632 million), AIHL generated revenues of ZAR 9.6 billion ($536 million) for the financial year ending June 2024. Founded in 1890, the company operates across four segments—prescription, consumer, over-the-counter (OTC), and hospitals. It has a diverse product portfolio ranging from generic and branded formulations to critical-care hospital products, as well as consumer and home-care products. The announcement was made after market hours. On Wednesday, Natco Pharma's shares rose by 2.01 per cent, ending the day's trade at Rs 1,034.75 apiece on the Bombay Stock Exchange (BSE).
